Dr. Anna Katherine Krawisz, MD

Dr. Krawisz practices at Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health.

Dr. Krawisz's NPI, 1477986222, was assigned on August 15, 2013. Dr. Krawisz graduated from Stanford University School of Medicine in 2013. Dr. Krawisz holds Massachusetts license 270411.

Dr. Krawisz's primary practice is Beth Israel Deaconess Medical Center, at 330 Brookline Avenue, Boston, MA 02215 in Suffolk County. The practice phone is (617) 667-7000.

Dr. Krawisz's primary practice is Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health. Dr. Krawisz is also affiliated with Beth Israel Deaconess Hospital-Needham. The medical group on file is Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center (HMFP). Dmand AI also links Dr. Krawisz to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Krawisz practices, 5 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Krawisz's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Krawisz is licensed in Massachusetts.

CMS data shows 561 Medicare services from Dr. Krawisz across 10 procedure codes in 2024, for 332 Medicare patients. Medicare paid $36,339 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 332 Medicare patients who saw Dr. Krawisz in 2024. The largest group is 75 to 84, with 130 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 29% are also on Medicaid. Their average risk score is 2.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Krawisz's median patient age at 72, with 51% women.

In 2024, Dr. Krawisz wrote 729 Medicare Part D claims for 102 patients. 95% of them were for generic drugs. CMS names the drug for 648 of them, across 20 drugs with 11 or more claims each, at $35,044 in total drug cost. In 2023, CMS named 159 claims across 9 drugs.

Dr. Krawisz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Krawisz as offering telehealth.

Dmand AI links 22 papers to Dr. Krawisz, published from 2019 to 2025. 2024 was the busiest year, with 4. The most frequent topics are Peripheral Arterial Disease, Endovascular Procedures and Femoral Artery. Dr. Krawisz has published most often in EuroIntervention. Dr. Krawisz's most frequent co-authors are Eric Alexander Secemsky, MD, MS, Brett Joseph Carroll, MD and Jennifer L. Cluett, MD.

CMS Open Payments shows 11 general payments to Dr. Krawisz from 2 drug and device companies from 2019 to 2025. Speaker and faculty fees make up the largest share, 74% of the total. Medtronic, Inc. paid the most, $1,790.

Dr. Krawisz graduated from Stanford University School of Medicine in 2013.